Yanqing Kan
Pfizer (United States)(US)
Publications by Year
Research Areas
Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling, Chronic Kidney Disease and Diabetes, Regulation of Appetite and Obesity, Pancreatic function and diabetes
Most-Cited Works
- → Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun(1998)181 cited
- → Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.(2000)126 cited
- → Regulation of Energy Homeostasis by Bombesin Receptor Subtype-3: Selective Receptor Agonists for the Treatment of Obesity(2010)87 cited
- → Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity(2010)65 cited
- → Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity(2012)62 cited
- → Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis(2020)53 cited
- → Antiobesity Effect of MK-5046, a Novel Bombesin Receptor Subtype-3 Agonist(2010)49 cited
- → An integrin antagonist (MK‐0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model(2017)46 cited
- → Discovery of Benzodiazepine Sulfonamide-Based Bombesin Receptor Subtype 3 Agonists and Their Unusual Chirality(2011)44 cited